{"title":"First report of amphotericin B resistant Candida haemulonii isolated from the ICU of a referral hospital in Indonesia","authors":"Rifdah Hanifah, Mardiastuti Wahid, Andi Yasmon","doi":"10.18502/ijm.v16i2.15363","DOIUrl":null,"url":null,"abstract":"Background and Objectives: Amphotericin B is a broad-spectrum antifungal agent commonly used to treat Candida haemulonii infection. C. haemulonii was isolated from patients reported to be intrinsically resistant to amphotericin B, en- coded by the ERG2 and ERG11 genes. However, there have been limited studies concerning amphotericin B-resistant C. haemulonii in Indonesia. The objective of this study is to explore the phenotypic and genotypic characteristics (ERG2 and ERG11) of C. haemulonii isolated from the ICU of a referral hospital in Indonesia. \nMaterials and Methods: Identification and susceptibility tests were conducted using VITEK2. Thereafter, DNA was ex-tracted and amplified using conventional PCR followed by DNA sequencing (Sanger method). \nResults: The results of the phenotypic susceptibility test showed that all C. haemulonii were resistant to amphotericin B. ERG2 and ERG11 sequences showed the same amino acid sequence and corresponded to references that are resistant to amphotericin B. \nConclusion: The resistant properties of C. haemulonii against amphotericin B found in this study require further exploration, including comparing resistant and sensitive C. haemulonii to amphotericin B. In addition, it is necessary to analyze other genes besides ERG2 and ERG11.","PeriodicalId":14633,"journal":{"name":"Iranian Journal of Microbiology","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijm.v16i2.15363","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and Objectives: Amphotericin B is a broad-spectrum antifungal agent commonly used to treat Candida haemulonii infection. C. haemulonii was isolated from patients reported to be intrinsically resistant to amphotericin B, en- coded by the ERG2 and ERG11 genes. However, there have been limited studies concerning amphotericin B-resistant C. haemulonii in Indonesia. The objective of this study is to explore the phenotypic and genotypic characteristics (ERG2 and ERG11) of C. haemulonii isolated from the ICU of a referral hospital in Indonesia.
Materials and Methods: Identification and susceptibility tests were conducted using VITEK2. Thereafter, DNA was ex-tracted and amplified using conventional PCR followed by DNA sequencing (Sanger method).
Results: The results of the phenotypic susceptibility test showed that all C. haemulonii were resistant to amphotericin B. ERG2 and ERG11 sequences showed the same amino acid sequence and corresponded to references that are resistant to amphotericin B.
Conclusion: The resistant properties of C. haemulonii against amphotericin B found in this study require further exploration, including comparing resistant and sensitive C. haemulonii to amphotericin B. In addition, it is necessary to analyze other genes besides ERG2 and ERG11.
背景和目的:两性霉素 B 是一种广谱抗真菌药物,常用于治疗血念珠菌感染。据报道,从患者体内分离出的血念珠菌对ERG2和ERG11基因编码的两性霉素B具有内在耐药性。然而,有关印度尼西亚耐两性霉素 B 的 C. haemulonii 的研究还很有限。本研究旨在探讨从印度尼西亚一家转诊医院重症监护室分离出的血吸虫的表型和基因型特征(ERG2和ERG11)。材料与方法:使用 VITEK2 进行鉴定和药敏试验,然后使用常规 PCR 提取和扩增 DNA,再进行 DNA 测序(桑格方法)。结果ERG2和ERG11序列显示了相同的氨基酸序列,并与对两性霉素B有抗药性的参照物相对应:本研究中发现的血球孢子菌对两性霉素 B 的耐药性需要进一步探讨,包括比较血球孢子菌对两性霉素 B 的耐药性和敏感性。
期刊介绍:
The Iranian Journal of Microbiology (IJM) is an international, multi-disciplinary, peer-reviewed journal that provides rapid publication of the most advanced scientific research in the areas of basic and applied research on bacteria and other micro-organisms, including bacteria, viruses, yeasts, fungi, microalgae, and protozoa concerning the development of tools for diagnosis and disease control, epidemiology, antimicrobial agents, clinical microbiology, immunology, Genetics, Genomics and Molecular Biology. Contributions may be in the form of original research papers, review articles, short communications, case reports, technical reports, and letters to the Editor. Research findings must be novel and the original data must be available for review by the Editors, if necessary. Studies that are preliminary, of weak originality or merely descriptive as well as negative results are not appropriate for the journal. Papers considered for publication must be unpublished work (except in an abstract form) that is not under consideration for publication anywhere else, and all co-authors should have agreed to the submission. Manuscripts should be written in English.